PRO-ACT: Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver
Latest Information Update: 04 Mar 2021
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary) ; Sofosbuvir/velpatasvir/voxilaprevir
- Indications Hepatitis C
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms PRO-ACT
- 02 Oct 2020 Status changed from active, no longer recruiting to completed.
- 17 Sep 2020 New trial record
- 14 Sep 2020 Primary endpoint (Sustained virologic response at 12 weeks post-transplant (SVR12) has been met according to the results published in the Hepatology